As announced on December 11, 2025, we entered into a definitive agreement (the “Merger Agreement”) with Cycle, a United Kingdom-based company focused on rare genetic conditions in metabolic, ...
As previously disclosed, Chembio Diagnostics, Inc. (“Chembio” or the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”), dated as of January 31, 2023, with Biosynex SA, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results